"MOVE along now, nothing to see." Constable Plod's old refrain looks an apt way to sum up Criterion's performance in the March quarter, with his "buy" calls rising an average 1 per cent in a quarter in which the broader market surged 5 per ...
Tags: economy
At least $200 million will be invested into early stage, high growth Australian companies by three new venture capital funds supported by the federal government’s Innovation Investment Fund (IIF). The IIF is a Government vehicle ...
Tags: venture capital funds, Bionomics, Pharmaxis
The sharemarket broke a 10-day winning streak yesterday after the US Federal Reserve said the country's economy had paused recently. However, the Australian bond market found support after a wave of selling. "Being the last day of the ...
Tags: stocks, US economy, sharemarket
The Australian sharemarket has closed slightly weaker, snapping a 10-day winning streak, after markets in the US fell. At 4.15pm AEDT, the benchmark S&P/ASX 200 index had fallen 17.9 points, or 0.37 per cent, at 4878.8 points, and the ...
Tags: Stocks, sharemarket, Ordinaries index
The European Commission has granted marketing authorization for Pharmaxis' Bronchitol as an add on therapy to cystic fibrosis (CF). The company developed Bronchitol to aid clear the airways of CF patients. Pharmaxis CEO Alan Robertson ...
Tags: cystic fibrosis, CF, Pharmaxis'Bronchitol